LCN2 / NGAL Antibody

LCN2 / NGAL Antibody Datasheet

LCN2 / NGAL Antibody Product Information

• Immunogen: Recombinant Human LCN2 / NGAL protein (Catalog#10222-H08H)
• Antibody Type: Rabbit Monoclonal Antibody ( Rabbit mAb Service Platform )
• Clone ID: 210
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was obtained from a rabbit immunized with purified, recombinant Human LCN2 / NGAL (rh LCN2 / NGAL; Catalog#10222-H08H; NP_005555.2; Met 1-Gly 198).

LCN2 / NGAL Antibody Usage Guide

• Specificity: Human LCN2 / NGAL
• No cross-reactivity in ELISA with

  Human MMP9

  Rat LCN2

• Direct ELISA: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human LCN2. The detection limit for Human LCN2 is approximately 0.00975 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

LCN2 / NGAL Antibody Background

Lipocalin-2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL), was originally identified as a protein stored in specific granules of the human neutrophil and has interaction with neutrophil gelatinases (MMP-9). NGAL is expressed in bone marrow and most tissues that are prone to exposure to microorganisms, and is synthesized in granulocytes and epithelial cells in pathological conditions, such as inflammation and malignancy. Lipocalin-2 has been implicated in a variety of processes including cell differentiation, proliferation, survival and morphogenesis. In addition, NGAL is expressed in a variety of tumor types including breast, ovary and pancreatic carcinomas, and it is suggested that lipocalin-2 has at least two functions related to tumorigenesis, one involving apoptosis induction of normal hematopoietic cells and the other being tissue invasion by leukemia cells. Recent studies have revealed that NGAL plays an important role in the physiopathology of chronic myeloid leukaemia (CML) mediated by BCR-ABL.

References

1. Kjeldsen, L. et al., 1993, J. Biol. Chem. 268: 10425-10432.
2. Cowland, J.B. et al., 1997, Genomics. 45: 17-23.
3. Zereqa, B. et al., 2000, Eur. J. Cell. Biol. 79: 165-172.
4. Fernanadez, C.A. et al., 2005, Clin. Cancer. Res. 11: 5390-5395.
5. Villalva, C. et al., 2008, Leuk. Lymphoma. 49: 984-988.